$-0.19 EPS Expected for Corbus Pharmaceuticals Holdings (CRBP); SMTC (SMTX)’s Sentiment Is 2.67

August 8, 2017 - By Marguerite Chambers

Analysts expect Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to report $-0.19 EPS on August, 21.They anticipate $0.08 EPS change or 72.73% from last quarter’s $-0.11 EPS. After having $-0.16 EPS previously, Corbus Pharmaceuticals Holdings Inc’s analysts see 18.75% EPS growth. It closed at $6 lastly. It is down 152.94% since August 8, 2016 and is uptrending. It has outperformed by 136.24% the S&P500.

SMTC Corporation is a provider of electronics manufacturing services (EMS). The company has market cap of $20.85 million. The Company’s manufacturing services include product design and sustaining engineering services, printed circuit board assembly (PCBA), production, enclosure fabrication, systems integration and testing services, configuration to order, build to order and direct order fulfillment. It currently has negative earnings. The Company’s geographic divisions include the United States, Mexico and China.

Since January 1, 0001, it had 5 buys, and 0 insider sales for $90,297 activity.

The stock increased 2.48% or $0.03 on August 7, reaching $1.24. About shares traded. SMTC Corporation (USA) (SMTX) has declined 18.75% since August 8, 2016 and is downtrending. It has underperformed by 35.45% the S&P500.

Wynnefield Capital Inc holds 0.79% of its portfolio in SMTC Corporation (USA) for 1.43 million shares. Grt Capital Partners L.L.C. owns 95,545 shares or 0.04% of their US portfolio. Moreover, Gilman Hill Asset Management Llc has 0.01% invested in the company for 15,977 shares. The New York-based Two Sigma Securities Llc has invested 0.01% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 12,425 shares.

Among 4 analysts covering Corbus Pharma (NASDAQ:CRBP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corbus Pharma had 8 analyst reports since September 8, 2015 according to SRatingsIntel. Noble Financial maintained the stock with “Buy” rating in Thursday, June 15 report. JMP Securities initiated Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) on Tuesday, September 8 with “Mkt Outperform” rating. As per Monday, July 17, the company rating was maintained by Cantor Fitzgerald. On Wednesday, October 5 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The firm earned “Buy” rating on Friday, November 11 by Noble Financial. The rating was initiated by Aegis Capital on Monday, March 7 with “Buy”. On Thursday, March 30 the stock rating was maintained by Cantor Fitzgerald with “Overweight”. The firm has “Buy” rating given on Tuesday, June 13 by Cantor Fitzgerald.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $301.31 million. The Firm is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. It currently has negative earnings. The Firm operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com